Dataset Information


Anti-claudin-4 extracellular domain antibody enhances the antitumoral effects of chemotherapeutic and antibody drugs in colorectal cancer.

ABSTRACT: Claudin-4 (CLDN4) is a major epithelial tight junction protein overexpressed in many cancers to maintain the tumor environment. In this report, we aimed to determine the efficacy of targeting CLDN4 in colorectal cancer (CRC) using an anti-CLDN4 extracellular domain antibody, 4D3. CLDN4 was upregulated in CRC metastatic foci. CLDN4 expression in CRC cells was reduced by upregulation of TNF?, which was induced by Clostridium perfringens enterotoxin produced by gut flora. In a nude mouse liver metastasis model, inhibition of metastasis was increased by combination treatment with 5-fluorouracil (FU) and 4D3 compared to that with 5-FU alone. Moreover, combination treatment with 4D3 and anti-epithelial growth factor receptor (EGFR) antibody C225 resulted in more pronounced inhibition of in vitro sphere formation and tumor growth in nude mice compared to that observed with C225 alone. Moreover, the time interval between the administration of 4D3 and that of C225 was important for maximizing the C225-induced inhibition of EGFR phosphorylation. In a nude mouse model, sequential treatment with 4D3 and C225 with a 6-h time interval resulted in more pronounced inhibition of tumor growth than concurrent treatment. These findings suggest that the targeting of CLDN4 enhances the antitumoral effects of chemotherapeutic agents and molecular targeting antibodies when used in combination.

PROVIDER: S-EPMC6324772 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC7226188 | BioStudies
| S-EPMC6481338 | BioStudies
| S-EPMC5898739 | BioStudies
2014-01-01 | S-EPMC4265789 | BioStudies
2014-01-01 | S-EPMC4046795 | BioStudies
2016-01-01 | S-EPMC5216764 | BioStudies
| S-EPMC5593639 | BioStudies
| S-EPMC8742403 | BioStudies
| S-EPMC8456648 | BioStudies
| S-EPMC5004687 | BioStudies